Anti-CD3 monoclonal antibody
Alternative Names: Bispecific immunoadhesion antibody; Monovalent anti-CD3; Monovalent anti-CD3 monoclonal antibodyLatest Information Update: 24 Oct 2021
At a glance
- Originator University of Cambridge; University of Oxford
- Developer INSERM; Necker Hospital; Nextran; University of Cambridge; University of Chicago
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Renal transplant rejection; Transplant rejection; Type 1 diabetes mellitus
Most Recent Events
- 17 Apr 2002 No development reported - Preclinical for Transplant rejection (unspecified route)
- 17 Apr 2002 No development reported - Preclinical for Type-1 diabetes mellitus in France (unspecified route)
- 17 Apr 2002 No development reported - Preclinical for Type-1 diabetes mellitus in USA (unspecified route)